Effect of individualizing starting doses of a statin according to baseline LDL-cholesterol levels on achieving cholesterol targets: the achieve cholesterol targets fast with atorvastatin stratified titration (ACTFAST) study by Martineau, P. et al.
AA
(
u
M
S
8
S
5
o
C
r
w
©
K
0
dAtherosclerosis 191 (2007) 135–146
Effect of individualizing starting doses of a statin according to
baseline LDL-cholesterol levels on achieving cholesterol targets:
The Achieve Cholesterol Targets Fast with Atorvastatin
Stratified Titration (ACTFAST) study
P. Martineau a, A. Gaw b, E. de Teresa c, C. Farsang d, G.F. Gensini e,
L.A. Leiter f, A. Langer f,g,∗,
on behalf of the ACTFAST investigators1
a Medical Division, Pfizer Canada, Kirkland, Que., Canada
b University of Glasgow, Glasgow, UK
c University of Malaga, V. de la Victoria Hospital, Malaga, Spain
d First Department of Medicine, Semmelweis University, Budapest, Hungary
e University of Florence, Careggi Hospital, Firenze, Italy
f St. Michael’s Hospital, University of Toronto, Toronto, Ont., Canada
g Canadian Heart Research Centre, 438 University Avenue, Suite 300, Toronto, Ont., Canada M5G-2P9
Received 12 July 2005; received in revised form 14 February 2006; accepted 3 March 2006
Available online 27 April 2006
bstract
ims: To investigate whether selecting the starting dose of atorvastatin according to baseline and target (<2.6 mmol/L) LDL-cholesterol
LDL-C) values would allow high-risk subjects to achieve target LDL-C concentration within 12 weeks, with the initial dose or a single
ptitration.
ethods and results: Twelve-week, prospective, open-label trial that enrolled 2117 high-risk subjects (statin-free [SF] or statin-treated [ST]).
ubjects with LDL-C >2.6 mmol/L (100 mg/dL) but ≤5.7 mmol/L (220 mg/dL) were assigned a starting dose of atorvastatin (10, 20, 40 or
0 mg/day) based on LDL-C and status of statin use at baseline, with a single uptitration at 6 weeks, if required. There was no washout for
T subjects. At study end, 80% of SF (82%, 82%, 83% and 72% with 10, 20, 40 and 80 mg, respectively) and 59% of ST (60%, 61% and
1% with 20, 40 and 80 mg, respectively) subjects reached LDL-C target. In the ST group, an additional 21–41% reduction in LDL-C was
bserved over the statin used at baseline. Atorvastatin was well tolerated.
onclusion: This study confirms that individualizing the starting dose of atorvastatin according to baseline and target LDL-C values (i.e. the
equired LDL-C reduction), allows a large majority of high-risk subjects to achieve target safely, within 12 weeks, with the initial dose or
ith a single titration.
2006 Elsevier Ireland Ltd. All rights reserved.
sity lipoeywords: Statins; HMG CoA reductase inhibitors; Atorvastatin; Low den∗ Corresponding author.
E-mail address: Langera@chrc.net (A. Langer).
1 See Appendix A for complete list.
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. IntroductionMost current guidelines for the treatment of dyslipidemia
n adults recommend more aggressive lipid-lowering targets
or subjects who are at high risk for cardiovascular events.
his includes subjects with established coronary heart dis-
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uncontrolled hypertension (>160/100 mmHg), uncontrolled
primary hypothyroidism (thyroid stimulating hormone ≥1.5
times the upper limit of normal), evidence of gastrointesti-36 P. Martineau et al. / Athe
ase (CHD) or CHD-equivalents such as diabetes, and those
symptomatic subjects with a 10-year CHD risk greater than
0%. HMG Co-A reductase inhibitors (statins) are recom-
ended as the initial drug of choice [1–4].
Despite the widespread availability of effective statins,
any patients do not reach their LDL-C targets, and thus,
ay not achieve the degree of reduction in cardiovascu-
ar events observed in landmark trials. Surveys reveal that
nder-treatment of dyslipidemia remains a significant health-
are concern worldwide. A survey conducted in the USA
evealed that although primary care physicians claimed a
ood level of awareness of lipid management guidelines,
nly 18% of subjects with CHD achieved a LDL-C target
f 2.6 mmol/L (<100 mg/dL) [5]. A European survey of sub-
ects with CHD conducted in 1999–2000, observed that the
umber of subjects with a total cholesterol ≥5.0 mmol/L
193 mg/dL) had dropped from 86% to 59% and that the pro-
ortion of subjects using lipid-lowering therapy had increased
rom 32% to 63% (from 19% to 58% for statins, specifi-
ally) since the previous survey conducted 5 years earlier
6]. Although, as a consequence of the increased use of
tatins, the proportion of subjects reaching a total choles-
erol target of less than 5.0 mmol/L (193 mg/dL) increased
rom 21% to 49%, this level of goal attainment is still
ub-optimal [6,7]. More recently, the ALLIANCE study,
onducted in a managed-care setting, reported that only
0% of secondary prevention subjects assigned to usual
are achieved a LDL-C target of <2.6 mmol/L (100 mg/dL)
ompared to 72% in those assigned to aggressive man-
gement with atorvastatin (P < 0.001), leading to a 17%
eduction in the incidence of major cardiovascular events
P = 0.02) [8]. Under-usage of statins has also been reported
n subjects with diabetes and acute coronary syndromes
9–11].
Factors which may prevent achievement of targets include:
ack of follow-up for uptitration, lack of adherence to therapy,
iscommunication between patient and physician, compla-
ency with sub-optimal cholesterol values achieved, confu-
ion around recommended lipid targets, patient or physician
references, and selection of an inappropriate starting dose.
t is a widespread medical practice to initiate statin treat-
ent at the lowest dose. Unfortunately, it is also common that
oses are not titrated up in order to reach the recommended
DL-C goal [12–14]. Tailoring the starting dose according
o individual LDL-C reduction requirements may aid in the
chievement of target LDL-C levels [12,15]. There is evi-
ence to suggest that baseline LDL-C levels impact overall
DL-C reduction, [16–18] and that treatment with intensive
ipid lowering therapy results in greater reductions in LDL-C
nd a higher proportion of subjects achieving targets com-
ared with more moderate regimens [19–29]. Thus, selecting
n initial starting dose calculated to achieve the required
DL-C reduction, may allow more patients to reach tar-
ets more quickly, reducing the need for dose increases, thus
mproving clinical outcomes and being more cost-effective
n the long term [30,31].
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Atorvastatin has been shown to reduce LDL-C levels by
p to 60% and is well tolerated [32]. No additional safety or
olerability concerns were observed when LDL-C levels were
educed to <2.1 mmol/L (80 mg/dL) [33,34]. Atorvastatin has
een shown to halt the progression of atherosclerosis [35–37],
nd to reduce the incidence of cardiovascular events in both
rimary and secondary prevention of CHD [8,38–40].
The Achieve Cholesterol Targets Fast with Atorvastatin
tratified Titration (ACTFAST) trial was designed to assess
hether using atorvastatin at starting doses appropriate for
he degree of LDL-C reduction required would achieve LDL-
targets quickly with either no titration or just one titration
tep, regardless of statin use at baseline.
. Methods
.1. Patient population
ACTFAST is a 12-week, multicenter, prospective, open-
abel trial assessing the effectiveness of using starting doses
f atorvastatin that are selected based on the baseline LDL-
value and on the required LDL-C reduction to reach
arget. Men and women aged at least 18 years old were
ligible for inclusion if they had been diagnosed with dys-
ipidemia defined as LDL-C of >2.6 mmol/L (100 mg/dL)
nd ≤5.7 mmol/L (220 mg/dL) at screening, had a triglyc-
ride level ≤6.8 mmol/L (600 mg/dL), and had a history of
HD, a CHD-equivalent (diabetes, cerebrovascular disease
r peripheral vascular disease) or an estimated 10-year CHD
isk >20% as per the Framingham tables [2]. Subjects could
e either statin-free or statin-treated at baseline. The subject
lso had to be willing to follow the NCEP III multifaceted
ifestyle approach (or local equivalent) [2].
Subjects were considered ineligible for the study if they
ere receiving therapy with any statin at a dose >40 mg/day,2
torvastatin, fibrates, niacin or resins that could not be discon-
inued a minimum of 2 months prior to enrolment, or received
rugs that are strong inhibitors of CYP3A4 or were likely
o receive such treatment during the study period. Subjects
ho used atorvastatin at screening were not eligible since the
tudy aimed at assessing the potential benefits of switching
ver from the statin used at baseline to a flexible starting dose
f atorvastatin. Subjects were also excluded if they had par-
icipated in any other study, suffered from specific systemic
iseases including impaired hepatic (defined as aspartate
minotransferase (AST) or alanine aminotransferase (ALT)
2 times the upper limit of normal) or renal function (creati-
ine ≥181mol/L), uncontrolled diabetes (HbA1c > 10%),2 Rosuvastatin became commercially available in Canada and the UK dur-
ng the trial and the Steering Committee allowed subjects on 10mg to be
nrolled in the study.
P. Martineau et al. / Atherosclero
Fig. 1. Study design and dose assignment based on baseline LDL-C levels
for statin-free subjects (no prior statin therapy within 2 months of screening).
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Wtatin-treated subjects (current statin therapy but LDL-C above target values)
eceived double the atorvastatin dose for the same baseline LDL-C levels
subjects with LDL-C 4.5–5.7 mmol/L all received the 80 mg dose).
al disease limiting drug absorption or partial ileal bypass,
levation of creatine kinase (CK) level (defined as >3 times
he upper limit of normal), alcohol and/or any other drug
buse, history of intolerance or hypersensitivity to statins, any
evere disease or surgical procedure within 3 months prior to
creening, or were women who were pregnant or lactating or
f childbearing potential not using an acceptable method of
ontraception.
The following medications were prohibited for the dura-
ion of the study: all other lipid-lowering medications, psyl-
ium (>2 tablespoons/day), orlistat, fish oils, terfenadine,
trong CYP3A4 inhibitors such as macrolide antibiotics, sys-
emic azole antifungals, or cyclosporine.
.2. Treatment
Subjects were assigned to 6 weeks of open-label treat-
ent with atorvastatin 10, 20, 40, or 80 mg according to
heir baseline LDL-C level and prior statin use, followed
y an additional 6-week open-label treatment during which
ubjects who had not reached target LDL-C levels, where
ossible, were titrated to the next highest dose of atorvastatin
Fig. 1). Subjects initially allocated to atorvastatin 80 mg who
id not reach LDL-C targets, were continued at that dose and
more intense therapeutic lifestyle intervention (NCEP II
tep 2 diet or equivalent) was recommended [2].
One week after the screening visit, subjects who had not
eceived statin therapy within 2 months of screening were
llocated to an atorvastatin dose in arm 1 (statin-free) accord-
ng to their baseline LDL-C level (Fig. 1). A subject’s LDL-C
oncentration in mg/dL was used to determine initial dose
ssignment and for decision-making regarding dose titration
t week 6. Subjects who had received prior statin therapy
excluding atorvastatin) but who’s LDL-C remained above
arget values were allocated to arm 2 (statin-treated), and
eceived double the atorvastatin dose for the same baseline
DL-C level as compared to their untreated counterparts,
ithout any washout period. Subjects with LDL-C between
d
n
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.5 and 5.7 mmol/L (170–220 mg/dL) all received the 80 mg
ose, regardless of treatment arm.
Blood samples were obtained at screening, weeks 6 and
2 for the measurement of 12 h fasting serum lipid profiles,
nd routine haematology and chemistry measurements that
ere part of the safety assessment. All cholesterol assays
ere performed by a central laboratory. Direct LDL-C mea-
urement was performed, regardless of triglyceride levels.
ubjects received dietary counselling at all visits. The rele-
ant institutional review boards approved the protocol, and
nformed consent was obtained from all subjects. This study
as conducted in compliance with the ethical principles of
he Declaration of Helsinki [41].
.3. Efficacy parameters
The primary efficacy outcome was the proportion of
ubjects achieving NCEP ATP-III target LDL-C levels of
2.6 mmol/L (<100 mg/dL) after 12 weeks of treatment [2].
econdary efficacy parameters included the proportion of
ubjects achieving total cholesterol/high density lipoprotein-
holesterol (TC/HDL-C) ratio target (<4.0) at 6 and 12 weeks,
nd mean percent change from baseline in TC, LDL-C, HDL-
, TC/HDL-C ratio, non-HDL-C, triglycerides and apo-B at 6
nd 12 weeks. Safety variables included treatment-emergent
dverse events defined as any adverse event reported after
dministration of at least one dose of study medication or
hat worsened in intensity or frequency after therapy began.
erious adverse events were defined as death or events that
ere life-threatening, that required or prolonged hospitaliza-
ion, that resulted in persistent or significant disability, and
ongenital anomalies.
.4. Lipid assays
Direct measurement of LDL-C was performed using a
omogeneous enzymatic colorimetric assay (LDL-C plus
econd generation, Roche Diagnostics GmbH) by a central
aboratory accredited for lipid assays by the CDC/NHLBI.
his assay is reliable with TG plasma values up to
200 mg/dL (13.5 mmol/L).
.5. Statistical analysis
Based on the results of NASDAC (15), where 69% of high-
isk subjects achieved LDL-C target, the dose assignment
able of ACTFAST was expected to allow 70% of subjects
o reach target. Although an ambitious target based on cur-
ent evidence of sub-optimal management of dyslipidemia in
igh-risk subjects (5–11), this value of 70% of subjects reach-
ng LDL-C target was determined to be clinically meaningful.
ith a sample size of 2020 subjects, a two-sided 95% confi-
ence interval for a single proportion using the large sample
ormal approximation will extend 2% from the observed pro-
ortion for an expected proportion of 70% overall. Based on
n estimated 3% dropout rate, enrolment of 2080 subjects was
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etermined. This sample size adequately addressed the study
ypothesis that atorvastatin treatment would enable subjects
o achieve their LDL-C target with either no, or just a single
itration step.
Data were analyzed on an intent-to-treat (ITT) and per-
rotocol basis. If data for a given visit were missing, this was
esolved by carrying forward the most recent non-missing on-
reatment data (last observation carried forward; LOCF). The
TT population consisted of all subjects who were assigned a
tarting dose, took at least one dose of study medication, and
ho had at least one subsequent assessment. Theper-protocol
opulation consisted of those subjects who completed the
tudy as per protocol, were exempt of major protocol vio-
ations and who were compliant with study treatment. The
afety population consisted of all subjects who took at least
ne dose of study medication.
Categorical efficacy variables are presented as counts
nd percentages. Continuous variables are summarized as
ean, standard deviation and 95% confidence intervals forhe mean. No inferential statistical tests were performed.
lthough allocation of doses was not randomized, data were
ummarized by initial dose allocation, as well as for all
oses combined, where appropriate. Safety parameters were
s
j
1
a
able 1
aseline characteristics—ITT population
haracteristics Statin-free (N = 1345)
ale (N, %) 877 (65.2)
aucasian (N, %) 1254 (93.2)
ean age (y) (mean ± S.D.) 63.0 ± 11.0
eight (kg) (mean ± S.D.) 82.3 ± 16.9
ody mass index (kg/m2) (mean ± S.D.) 29.3 ± 5.4
aist circumference (cm) (mean ± S.D.) 100.4 ± 13.7
ystolic/diastolic blood pressure (mmHg) (mean ± S.D.) 136.7 ± 16.3/79.4 ± 10
moking (N, %) 308 (22.9)
iabetes (N, %) 611 (45.4)
Proportion of type 2 diabetes (N, %) 594 (97.2)
HD (N, %) 675 (50.2)
erebrovascular disease (N, %) 126 (9.4)
eripheral vascular disease (N, %) 108 (8.0)
0-year CHD risk >20%a (N, %) 103 (7.7)
etabolic syndrome (N, %) 667 (49.6)
ypertension (N, %) 930 (69.1)
amily history of premature CHD (N,%) 292 (21.7)
urrent statin used at baselineb (N, %) Fibrates 11 (0.8)c, stat
(0.2)c, resins 1 (0.07)c
oncomitant medications (N, %)
ASA and other antiplatelet agents 838 (62.3)
Oral anticoagulants 93 (6.9)
Beta-blockers 495 (36.8)
ACE inhibitors 567 (42.2)
Angiotensin II receptor antagonists 206 (15.3)
CE: angiotensin converting enzyme; LLT: lipid lowering therapy.
a Subjects without CHD, CHD-equivalent or diabetes who qualified solely based
b In the statin-treated group, the distribution of the various statins was approxima
c These subjects were not eligible since any LLT at baseline was prohibited in the s
d These 10 subjects were using other LLT (ezetimibe, fibrates, cholestyramine and
ere included in intention-to-treat analyses.sis 191 (2007) 135–146
ummarized overall and by initial dose allocation. The Steer-
ng Committee designed the trial in collaboration with the
ponsor, oversaw the conduct of the trial and led the prepara-
ion of the manuscript. Data co-ordination and production of
ata tables were performed by Pfizer Canada Inc. The Steer-
ng Committee and the sponsor performed the data analysis
ointly. Statistical analysis was performed using SAS Version
.2.
. Results
Between January and November 2003, 2859 subjects were
creened from 138 sites in Canada, Italy, Spain and the United
ingdom (Appendix A) and 2187 were assigned to study
rug. Of the 672 screening failures, 91% were due to the
ubject not meeting entry criteria. Thirty-three subjects did
ot provide a post-baseline assessment of blood cholesterol
nd 37 did not receive study medication. Consequently, the
afety population comprised 2150 subjects, and 2117 sub-
ects (96.8%) were included in the ITT population (686 on
0 mg (32.4%), 773 on 20 mg (36.5%), 234 on 40 mg (11.1%)
nd 424 on 80 mg (20.0%)). The proportion of subjects who
Statin-treated (N = 772) All subjects (N = 2117)
552 (71.5) 1429 (67.5)
724 (93.8) 1978 (93.4)
63.5 ± 10.1 63.2 ± 10.7
80.5 ± 14.7 81.6 ± 16.1
28.6 ± 4.6 29.0 ± 5.1
99.2 ± 12.6 99.9 ± 13.3
.0 133.4 ± 16.9/76.9 ± 10.1 135.5 ± 16.6/78.5 ± 10.1
146 (18.9) 454 (21.4)
217 (28.1) 828 (39.1)
211 (97.2%) 805 (97.2)
625 (81.0) 1300 (61.4)
77 (10.0) 203 (9.6)
67 (8.7) 175 (8.3)
15 (1.9) 118 (5.6)
315 (40.8) 982 (46.4)
509 (65.9) 1439 (68.0)
197 (25.5) 489 (23.1)
ins 3 Fluvastatin 56 (7.3), lovastatin 42
(5.4), pravastatin 238 (30.8),
rosuvastatin 6 (0.8), simvastatin
427 (55.3), other LLT 10 (1.3)d
691 (89.5) 1522 (71.9)
37 (4.8) 130 (6.1)
433 (56.1) 928 (43.8)
399 (51.7) 966 (45.6)
105 (13.6) 311 (14.7)
on a 10-year CHD risk >20%.
tely the same across the 20, 40 and 80 mg doses of atorvastatin.
tatin-free group. These subjects were included in intention-to-treat analyses.
niacin) at baseline and thus, were not eligible for the study. These subjects
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Table 2
Baseline laboratory values—ITT population (mean (S.D.))
Value Statin-free (N = 1345) Statin-treated (N = 772) All subjects (N = 2117)
Fasting glucose (mmol/L) 6.7 (2.4) 6.3 (2.0) 6.5 (2.3)
HbA1C (%) 6.4 (1.2) 6.3 (1.1) 6.4 (1.1)
Total cholesterol (mmol/L) 5.8 (0.9) 5.4 (0.8) 5.7 (0.8)
LDL-C (mmol/L) 3.9 (0.7) 3.5 (0.6) 3.7 (0.7)
HDL-C (mmol/L) 1.3 (0.3) 1.3 (0.3) 1.3 (0.3)
TC/HDL ratio 4.8 (1.2) 4.4 (1.0) 4.7 (1.2)
T
A
N
c
1
(
r
(
h
m
e
L
T
g
t
<
7
s
p
d
c
s
i
(
i
a
s
s
6
F
(
(
C
w
(
w
a
s
f
8
a
t
t
f
(
i
r
f
s
n
a
i
a
a
(riglycerides (mmol/L) 1.9 (1.0)
po-B (g/L) 1.1 (0.2)
on-HDL-C 4.6 (0.8)
ompleted the study was 95%, 95%, 94% and 90% for the
0, 20, 40 and 80 mg doses, respectively.
Participants were mainly Caucasians (93%) and male
68%), with a mean age of 63 years. Overall, 21% were cur-
ent smokers, 39% had diabetes, and 61% had prior CHD
Table 1). There was a lower prevalence of diabetes and
igher prevalence of CHD in the statin-treated group. The
ean baseline laboratory values are illustrated in Table 2. As
xpected from the dose assignment scheme based on baseline
DL-C and status of statin use at baseline, the mean baseline
C, LDL-C, non-HDL-C and TC/HDL-C differed between
roups.
Using the LOCF analysis, the primary efficacy parame-
er, the proportion of subjects achieving LDL-C targets of
2.6 mmol/L (100 mg/dL) after 12 weeks of treatment, was
2.0% overall, and 79.6% and 58.7% for statin-free and
tatin-treated subjects, respectively. Fig. 2 illustrates the pro-
ortion of subjects achieving LDL-C target on each initial
ose for both the statin-free and statin-treated groups. When
onsidering the per protocol population, the proportions of
ubjects achieving targets were slightly higher, most notably
n the statin-free group (Fig. 3).
Among statin-free subjects who achieved target
N = 1071), over 90% achieved their LDL-C target with the
nitial dose (91%, 90%, 90% and 96% for the 10, 20, 40
nd 80 mg doses, respectively). Among the statin-treated
ubjects who achieved target (N = 453), the proportions of
ubjects who accomplished this at initial dose were 72%,
4% and 96% with the 20, 40 and 80 mg doses, respectively.
ig. 2. Proportion of subjects reaching LDL-C target of <2.6 mmol/L
100 mg/dL) by starting dose in the statin-free and statin-treated groups
intention to treat (N = 2117); last observation carried forward).
b
s
T
o
F
(
p1.9 (0.9) 1.9 (0.9)
1.1 (0.2) 1.1 (0.2)
4.1 (0.7) 4.4 (0.8)
onsidering statin-free subjects who required titration at
eek 6 from the 10 mg (N = 106), 20 mg (N = 30) and 40 mg
N = 17) doses, 80%, 80% and 94% of these, respectively,
ere uptitrated. Of these, 58%, 67% and 69% reached target
t week 12 with 10, 20 and 40 mg, respectively. Considering
tatin-treated subjects who required uptitration at week 6
rom the 20 mg (N = 260) and 40 mg (N = 33) doses, 90% and
8% of these, respectively, were uptitrated. Of these, 42%
nd 52% achieved target at week 12 on 20 and 40 mg, respec-
ively. Overall, in subjects assigned to 10, 20 or 40 mg doses,
he lack of uptitration in eligible subjects (N = 58) was due to
ailure of the investigator to uptitrate as required by protocol
N = 23; 40%), failure of the patient to follow the dosing
nstructions (N = 28; 48%) or to adverse events (N = 7; 12%).
Within each treatment group, the proportion of subjects
eaching target at weeks 6 and 12 was not significantly dif-
erent (Table 3). Since this result may have been biased by
ubjects who did not adhere to study medication or who did
ot attend the two study-assessment visits at least 3 weeks
part, an additional post hoc analysis was conducted, exclud-
ng these subjects from the per protocol analysis. Despite this
djustment, no difference was observed between the weeks 6
nd 12 achievement of LDL-C target in each treatment group
Table 3).
Mean percent changes in LDL-C were significant versus
aseline for all doses in both statin-free and statin-treated
ubjects. Similarly, significant change from baseline in TC,
C/HDL-C ratio, triglycerides, non-HDL-C and apo-B were
bserved with all doses in both statin-free and statin-treated
ig. 3. Proportion of subjects reaching LDL-C target of <2.6 mmol/L
100 mg/dL) by starting dose in the statin-free and statin-treated groups (per
rotocol population (N = 1652); last observation carried forward).
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Table 3
Proportion of subjects achieving LDL-C target at weeks 6 and 12, in statin-free and statin-treated groups—ITT population and the subset of per protocol
subjectsa who attended both weeks 6 and 12 assessments
Statin-free ITT (N = 1345) (%) (95% CI) Per protocol subjects who attended both visitsa (N = 1012)
(%) (95% CI)
Week 6 Week 12 Week 6 Week 12
10 mg 84.3 (81.5–87.0) 83.1 (80.3–86.0) 88.6 (85.9–91.3) 87.1 (84.3–90.0)
20 mg 83.4 (78.0–88.8) 80.7 (74.9–86.5) 86.3 (80.6–92.0) 84.2 (78.1–90.2)
40 mg 88.9 (83.9–93.9) 82.2 (76.2–88.2) 90.3 (85.1–95.5) 89.5 (84.1–94.9)
80 mg 79.9 (75.3–84.4) 72.1 (67.0–77.2) 82.4 (77.3–87.4) 78.3 (72.8–83.7)
All doses 83.7 (81.7–85.7) 80.1 (78.0–82.3) 87.2 (85.1–89.2) 85.1 (82.9–87.3)
Statin-treated ITT (N = 772) (%) (95% CI) Compliant subjects who attended both visitsa (N = 552)
(%) (95% CI)
Week 6 Week 12 Week 6 Week 12
20 mg 55.1 (51.0–59.2) 60.3 (56.3–64.3) 57.4 (52.8–62.0) 63.0 (58.5–67.5)
40 mg 55.4 (44.1–66.7) 60.3 (49.1–71.5) 57.1 (42.2–72.1) 59.5 (44.7–74.4)
80 mg 58.1 (48.7–67.5) 50.9 (41.5–60.4) 53.6 (41.9–65.4) 47.8 (36.0–59.6)
All doses 55.5 (52.0–59.1) 59.0 (55.5–62.5)
LOCF data is illustrated in Fig. 2.
a Subjects included in this sub-population, had to have their assessment visits for
F
d
l
s
s
t
t
a
w
1
d
C
b
p
r
a
D
b
t
≥
F
tig. 4. Proportion of subjects reaching TC/HDL-C target of <4.0 by starting
ose in the statin-free and statin-treated groups (intention to treat (N = 2117);
ast observation carried forward).ubjects (Table 4). Overall, 83% and 78% of statin-free and
tatin-treated subjects, respectively, achieved a TC/HDL-C
arget of <4.0 (Fig. 4). This result was improved slightly in
he per protocol population (87% and 80% for statin-free
3
1
ig. 5. Percent change from baseline in HDL-C according to baseline HDL-C <1.
reated arms (B). Intention to treat; last observation carried forward. *P < 0.05 from56.9 (52.8–61.0) 60.9 (56.8–64.9)
weeks 6 and 12 at least 21 days apart. ITT: intention-to-treat.
nd statin-treated subjects, respectively). Changes in HDL-C
ere minor and only significant compared to baseline with the
0 mg dose in statin-free subjects, and with the 20 and 80 mg
oses in the statin-treated group. In order to clarify the HDL-
effect, the study population was analyzed according to
aseline HDL-C < or ≥1.03 mmol/L (40 mg/dL), the cut-off
oint defined by NCEP-III for ‘low’ HDL-C (Fig. 5) [2]. The
esults show that, at any dose, an increase in HDL-C occurs
lmost exclusively in subjects with a low baseline HDL-C.
ata on subjects with intermediate HDL-C (40–45 mg/dL) at
aseline show an intermediate response, more closely related
o the HDL-C response of subjects with a baseline HDL-C
40 mg/dL (data not shown)..1. Safety
The incidence of treatment-related adverse events was
2.1%, across the dose range (Table 5). The most common
03 mmol/L (40 mg/dL) vs. ≥1.03 mmol/L in the statin-free (A) and statin-
baseline.
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vents reported with a global incidence >1% were: asthenia
1.6%), myalgia (1.4%), constipation (1.1%) and dyspepsia
1.1%). The majority of events were of mild to moderate
ntensity with severe adverse events reported in only 0.6%
f subjects. Overall, only 3.3% and 0.5% of subjects discon-
inued atorvastatin due to treatment-related adverse events
nd laboratory abnormalities, respectively. The most fre-
uently reported adverse events leading to discontinuation of
torvastatin were (in decreasing order of frequency): gastro-
ntestinal complaint, musculoskeletal complaint, abnormal
aboratory parameter and asthenia. Treatment-related adverse
vents involving the musculoskeletal system occurred in only
.3% of subjects. One case of rhabdomyolysis was reported
s a mild, non-serious event by an investigator. The rise in
K was modest (peak at 359 IU/L) and the subject completed
he study while remaining on the 80 mg dose. Upon review of
his case, the Steering Committee determined that it was not
onsistent with a diagnosis of rhabdomyolysis based on the
riteria defined in the ACC/AHA/NHLBI advisory on the
se and safety of statins [42]. No treatment-related serious
dverse events were reported. Two subjects died during the
tudy, both in the atorvastatin 20 mg group; one of a myocar-
ial infarction and the other of heart failure, neither of which
ere deemed treatment-related by the investigator. The inci-
ence of any rise in AST/ALT >3 times the upper limit of
ormal, regardless of causality, was low at 1.2%. There was
nly one case of CK >10 times the upper limit of normal,
hich occurred without accompanying muscle symptoms, in
statin-free subject assigned to the 80 mg dose (0.05% over-
ll). In this case, although the investigator reported the event
s drug-related, it must be highlighted that the subject had
ustained two falls 2 days before due to weak legs (due to
egenerative disease of the spine, which was present at base-
ine and was reported as not related to atorvastatin) and that
swollen right ankle was also documented on the day blood
as sampled. The possible contribution of these confounding
vents cannot be eliminated.
. Discussion
The ACTFAST study was designed to assess whether
sing atorvastatin at starting doses appropriate for the degree
f LDL-C reduction required would lead to achievement of
DL-C target quickly with either no titration or just one
itration step. Traditionally, treatment has involved initiating
herapy with the lowest dose of atorvastatin (i.e., 10 mg) and
itrating up over time, with more subjects achieving targets
ith higher doses [12]. Frequent medical visits for dose titra-
ion being costly and time-consuming, may lead to frustration
or patients and physicians alike [15]. In addition, Foley et
l reported that only 45% of high-risk subjects who did not
each goal with initial dose of a statin were uptitrated [14]. It
s interesting that, in this study, baseline lipid profile was not
ssociated with a greater likelihood of uptitration. In addi-
ion, uptitration was less likely in subjects where the statin
142 P. Martineau et al. / Atherosclerosis 191 (2007) 135–146
Table 5
Overview of safety
10 mg
(N = 698)
20 mg
(N = 784)
40 mg
(N = 240)
80 mg
(N = 428)
All doses
(N = 2150)
All causality
Subjects with AE (%) 37.4 34.3 37.1 44.9 37.7
Subjects with musculoskeletal AE (%) 6.2 5.7 6.3 7.0 6.2
AST or ALT >3 times upper limit of normala (%) 0.7 0.5 1.3 3.3 1.2
CK >10 times upper limit of normala (%) 0 0 0 0.2 0.05
Treatment-related AE
Subjects with AE (%) 10.7 7.9 16.7 19.4 12.1
Subjects with musculoskeletal AE (%) 1.7 1.8 3.3 3.5 2.3
Subjects discontinued due to AE (%) 2.7 2.4 5.0 5.1 3.3
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as initiated at doses above the recommended starting doses
nd when care was provided by a general practitioner.
Studies on subjects with CHD or diabetes have reported
hat about 32–59% of subjects will achieve targets with
starting dose of atorvastatin of 10 mg [15,17,18,26,29].
owever, an additional 29–51% of subjects will go on to
chieve targets when titrated to higher doses of atorvas-
atin (20–80 mg) [17,18,26,29]. Brown et al reported that
2% of subjects at higher risk achieved LDL-C targets of
2.6 mmol/L (100 mg/dL) after 12 weeks of therapy, and
ith dose titration up to 80 mg of atorvastatin, 83% were
ble to achieve this target [26]. In the NASDAC trial, there
as a greater likelihood of subjects with CHD or CHD-
quivalents to reach targets with higher starting doses (80.9%
ith 40 mg dose, 80.3% with 80 mg dose) than with lower
tarting doses (46.5% with 10 mg dose, 66.2% with 20 mg
ose) [15]. ACTFAST showed that by initiating therapy at
oses selected according to baseline LDL-C levels, 72% of
ll subjects, whether statin-free or statin-treated, achieved a
arget LDL-C of <2.6 mmol/L (100 mg/dL) as early as within
weeks. Interestingly, significant additional LDL-C reduc-
ions of 21–41% were observed at each dose when subjects
reated with another statin at baseline were switched to a given
ose of atorvastatin defined by the dose assignment table.
Changes in HDL-C concentrations were small and similar
o those observed in other studies [38,39,48]. As suggested by
hese studies, our results might have been influenced by the
ather high mean baseline HDL-C (1.3 mmol/L [50 mg/dL])
bserved in our subjects. Our data confirm the results of
ther studies, which reported that a significant rise in HDL-
occurs almost exclusively in subjects with a low baseline
DL-C (<1.03 mmol/L (40 mg/dL)) [43–45]. In this sub-
roup, HDL-C increased by 7–9% in a non-dose-related
ashion.
ACTFAST confirms that initiating treatment with a dose of
torvastatin selected to provide the required LDL-C reduction
ould bring a large proportion of high-risk subjects to LDL-
targets within 12 weeks. Despite the high cardiovascular
isk in this subject group and the low LDL-C target levels
<2.6 mmol/L (100 mg/dL)), 80% of statin-free, and 59%
e
l
a
r0 1.3 1.6 0.5
se; CK, creatine kinase.
f statin-treated subjects, achieved targets within 12 weeks.
n an 8-week, open-label study using a similar treatment
lgorithm, 81.1% of high-risk statin-free subjects achieved
DL-C target [48]. In contrast, in the NASDAC study, sub-
ects were randomized to a starting dose of 10–80 mg of
torvastatin, regardless of their baseline LDL-C value [15].
he proportion of subjects with 0–1 risk factors and with
HD/CHD-equivalent who achieved LDL-C targets (defined
s <4.1 mmol/L (160 mg/dL) and <2.6 mmol/L (100 mg/dL),
espectively) with 10, 20, 40 and 80 mg were 85%, 88%,
8% and 95%, and 47%, 66%, 81% and 80%, respectively.
his demonstrates that, as the LDL-C target is lowered, one
equires a higher starting dose in order to successfully achieve
arget. In contrast to NASDAC, high-risk statin-free subjects
n ACTFAST showed better results on 10 and 20 mg doses,
ecause baseline LDL-C was taken into account.
A dosing regimen that allows for a larger number of
ubjects to reach LDL-C target is expected to significantly
mprove cardiovascular outcomes, as illustrated by recent
tudies comparing aggressive treatment with atorvastatin to
sual care-based regimens [8,40]. Thus, shortening the delay
etween treatment initiation and achievement of LDL-C tar-
et is attractive and potentially beneficial. The recommenda-
ions from NCEP-III support the use of a higher initial dose
n subjects requiring a large LDL-C reduction to reach target
2]. Recently, several regulatory agencies around the world
for example: USA, Canada, Italy) have approved the use
f atorvastatin at starting doses ranging from 10 to 40 mg.
f required, the dose can then be titrated upward to a max-
mum of 80 mg in order to achieve LDL-C target. Subjects
ith CHD or CHD-equivalent have the lowest LDL-C target
nd may require higher doses. Thus, given the lack of safety
oncern in the initiation phase, it is logical to initiate therapy
sing a dose of atorvastatin that is appropriate for the required
DL-C reduction.
The results of the statin-treated group must be consid-
red separately from the statin-free subjects. Based on their
ower baseline blood pressure, fasting plasma glucose, TC
nd LDL-C, one can assume that these subjects had already
eceived therapy for their heightened cardiovascular risk
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evel. These subjects are more difficult to treat and exhibit a
ertain level of treatment resistance as they failed to achieve
DL-C target with their initial therapy. The results of ACT-
AST show that the dosing assignment table also worked for
he subjects who did not reach target while on another statin.
t must be remembered, however, that this study specifically
xcluded patients on atorvastatin at baseline and therefore
he results may only be applicable to switching from another
tatin to atorvastatin. In these statin-treated subjects, sig-
ificant additional reductions of 21–41% in LDL-C were
chieved with doses of 20–80 mg of atorvastatin. This is
mportant considering recent evidence from head-to-head tri-
ls which showed that more aggressive LDL-C lowering with
torvastatin 80 mg improved outcomes in subjects with acute
oronary syndromes and stopped atherosclerotic progression
n subjects with stable CHD or familial hypercholesterolemia
34–37].
The ratio of TC/HDL-C is a more sensitive and specific
ndex of cardiovascular risk than total cholesterol. For that
eason, it is used in some countries as a secondary target
f treatment [1,12]. The dose assignment scheme tested in
CTFAST allowed for a large majority of both statin-free
nd statin-treated subjects to achieve a target ratio of <4.0.
iven the large contribution of LDL-C and TG reductions to
chievement of the TC/HDL-C ratio and the modest HDL-
elevation provided by atorvastatin, it is not surprising that
lightly more statin-free subjects reached the TC/HDL-C tar-
et compared to the LDL-C target. The same is true for
he statin-treated subjects, although the contribution of the
hange in HDL-C to achievement of the TC/HDL-C target
as small.
No significant safety issues were observed when initiat-
ng atorvastatin at higher doses. In a recent review of pooled
esults from 44 trials involving 9416 subjects on atorvastatin,
here was no dose–response relationship for adverse events
nd laboratory abnormalities across the dose range [46]. In
ASDAC, the proportion of subjects with treatment-related
dverse events was 10.9%, 11.8%, 11.3% and 16.5% with
he 10, 20, 40 and 80 mg doses, respectively, which is com-
arable to our results [15]. In ATGOAL, 18.4% of high-risk
ubjects experienced treatment-related adverse events [48].
he proportion of subjects discontinuing treatment due to
reatment-related adverse events in ACTFAST (3.3%) is sim-
lar or slightly lower than what was observed in NASDAC
3.2%) and ATGOAL (4% overall and 6% in high-risk sub-
ects). In NASDAC, two subjects out of 919 exhibited a CK
ise >10 times the upper limit of normal and in ATGOAL,
here were no case out of 1295, while only one case in 2150
ubjects occurred in ACTFAST. When considering any rise
3 times the upper limit of normal in AST or ALT, there were
ix cases (0.7%) in NASDAC, two to six cases (0.3–0.9%) in
igh-risk subjects in ATGOAL and 26 (1.2%) in ACTFAST
15,48]. In a pooled analysis of the atorvastatin clinical trials
atabase, an incidence of 0.96% was reported across the dose
ange, which is consistent with our results [46]. As demon-
trated by other studies, the results from ACTFAST further
(
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onfirm the safety of the 80 mg dose of atorvastatin and con-
rm that it can be safely used as a starting dose in subjects at
igh risk for CHD and with a baseline LDL-C between 4.5
nd 5.7 mmol/L [34,35,47].
. Conclusion
Subjects with CHD or CHD-equivalent have the lowest
DL-C target (<2.6 mmol/L) and are likely to require higher
oses of statins in order to achieve goal. Given that the under-
reatment of elevated LDL-C in high-risk subjects is still a
ignificant health care issue, identifying ways to improve the
chievement of lipid targets in this population is critical.
ailoring the starting dose of atorvastatin according to the
equired level of LDL-C reduction and status of statin use at
aseline provides a solution to achieve this objective. Using
uch a regimen, the ACTFAST study demonstrated that a
arge majority of high-risk subjects were able to achieve their
DL-C target safely within 12 weeks, with the initial dose or
ith just a single titration step. These results provide clini-
ians with a simple strategy to manage dyslipidemia and help
ecrease CHD risk faster and more effectively in high-risk
ubjects.
cknowledgement
This trial was funded by Pfizer Inc.
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